中新社上海2月6日电 (记者 陈静)华东师范大学6日透露，该校生物学专家带领课题组在国际上首次发现了一类新型转化生长因子β受体I抑制剂，可完全抑制乳腺癌细胞的迁移，且无毒性。这将为乳腺癌的治疗开辟新径。

China news agency Shanghai February 6 (Reuters) (Reporter reiter)East China normal university 6 revealed,The school biology experts lead for the first time in the international research found a new transformation growth factor beta receptor I inhibitor,Can be completely inhibit breast cancer cell migration,And non-toxic.This will be for the treatment of breast cancer, open a new path.

　　该课题组由华东师大生命医学研究所教授刘明耀领衔，一直致力于肿瘤学基础和转化研究。据介绍，课题组利用计算机虚拟和细胞功能筛选，结合药物化学结构改造，获得了这一可强烈抑制乳腺癌细胞迁移的新型转化生长因子β受体I抑制剂。专家们还利用三种不同的动物模型试验，验证了上述结论；且在高于有效浓度的剂量下，新型转化生长因子β受体I抑制剂对实验动物没有毒性。

By the research institute of east China normal university life medical professor liumengyao led,Has been committed to oncology research foundation and transformation.According to introducing,His use of computer virtual and cell function screening,Combined with drug chemical structure transformation,Get the can strongly inhibit breast cancer cell migration into new growth factor beta receptor I inhibitor.Experts also use three different animal model test,Verify the above conclusion;And above the effective concentration of doses,The new transformation growth factor beta receptor I inhibitors on experimental animals have no toxic.

　　据华东师大方面介绍，国际肿瘤学权威期刊《美国国立癌症研究所杂志》(《Journal of the National Cancer Institute》)新近登载了这一研究新成果——《转化生长因子β受体I抑制剂高效安全抑制乳腺癌转移》。目前该课题组正继续推进此项研究，并有望短时间内将此科研成果推向临床。(完)

According to introduction to east China normal university,International journal of oncology authority[Journal of the national cancer institute]([Journal of the National Cancer Institute])The newly published this research new results --[Transformation of growth factor beta receptor I inhibitor effective safety inhibit breast cancer metastasis].The group is to continue to push forward the study,In a short time and is expected to the achievements in scientific research into the clinical.(finish)